Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

O. Guimarães, Patrícia; Quirk, Daniel; Holanda de Mendonça Furtado, Remo; Nigro Maia, Lília; Francisco Kerr Saraiva, José; de Oliveira Antunes, Murillo; Kalil Filho, Roberto; Vagner, Marie; M Soeiro, Alexandre; Pereira Tognon, Alexandre; Cordeiro Veiga, Viviane; A. de Martins, Priscilla; D F Moia, Diogo; Sampaio, Bruna; R.L. Assis, Silvia; V P Soares, Ronaldo; Pereira Almeida de Piano, Luciana; Castilho, Kleber; G.R.A.P. Momesso, Roberta; Monfardini, Frederico; Penna Guimarães, Hélio; Ponce de León, Darío; Dulcine, Majori; R.T. Pinheiro, Marcia; Mert Günay, Levent; Jasper Deuring, J.; Vicente Rizzo, Luiz; Koncz, Tamás; Berwanger, Otávio

doi:10.1056/nejmoa2101643

Public

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Published in New England Journal of Medicine • Jun 16, 2021

Authors:

Patrícia O. Guimarães

Daniel Quirk

Remo Holanda de Mendonça Furtado

Abstract

BACKGROUND: The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS: We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a...

Subject

Tofacitinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!